Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections are prevalent throughout the world. HIV infection increases the risk of HBV and HCV liver disease especially when HIV-associated immunodeficiency progresses. Aims and Objectives: This study was carried out with the objectives as follows: Estimation of the prevalence of HIV- Hepatitis co-infection, determine CD4+T lymphocyte count in co-infected patients, identify most common opportunistic infections in HIV – Hepatitis co- infection. Materials and Methods: A hospital-based, prospective, cross-sectional, and observational study was carried among people with confirmed HIV infection. HIV antibody, hepatitis B surface antigen (HBsAg), and HCV antibody tests were done in all patients visiting to integrated counseling and testing center. HIV, HBV, and HCV viral load were done in all serologically confirmed patients. In HBsAg positive patients various markers for hepatitis such as hepatitis B envelop antigen (HBeAg), anti-hepatitis B core antibody (HBcAb), and anti-hepatitis B envelop antibody were also done. Results: Out of 357 people living with HIV/AIDS (PLHA) patients 15/357 (4.20%) were co-infected with HBV, 03/357 (0.84%) were co-infected with HCV. The overall seroprevalence of Hepatitis virus (HBV+HCV) in PLHA patients was found to be 5.04% (18/357). CD4+T lymphocyte count <200 cells/μL was seen in 66/339 (19.4%), 04/15 (26.6%), and 03/03 (100%) patients of HIV mono-infected, HBV co-infected, and in HCV co-infected patients, respectively. HIV Viral load ≤1000 copies/mL was seen in 324 and 15 patients in HIV mono-infected and HIV- hepatitis co-infected patient, respectively. Among PLHA patients who were positive for HBsAg; 46.7% (n=7) patients had HBV viral load >2000 IU/mL. All hepatitis B co-infected patients were positive for HBcAb test; HBeAg was positive in 40% (n=06). All HBeAg positive were having viral load >2000 IU/mL. Conclusion: HIV-infected patients are more prone to hepatitis associated liver diseases and exposure to the HBV infection than the general population.
Background: Brucellosis is the most common zoonotic disease caused by Gram-negative coccobacillus belonging to genus Brucella. It is a recognized public health problem in developing countries including India. Aims and Objectives: The aims of these study were to determine the seroprevalance of brucellosis in population having occupation dealing with animals and thus are in close contact of animals. Materials and Methods: The study was conducted in semi-urban areas of central India. Blood samples were collected from personnel working in slaughter houses, meat shops, and veterinarians and their close contact and who are willing to participate in study. A total 102 samples collected randomly from butchers (n=20), veterinarians (n=29), and animal handlers (n=53) and were tested for Brucella abortus and Brucella melitensis by a commercial kit which allows the detection of both complete (IgG and IGM) and incomplete antibodies. Results: A total 102 subjects were included in the study and overall prevalence of brucellosis among high-risk group was found to be 2.9%. One veterinarian doctor was also found positive for both B. melitensis and B. abortus. Highest prevalence of brucellosis was found in veterinarians (6.8%) followed by animal handlers (1.8%), and none of the butcher was tested positive for any of the Brucella antibody. Conclusion: The present study screened all possible known high-risk groups for brucellosis and revealed that veterinarians have high chances of getting the infection. Occupation-related disease like brucellosis needs regular surveillance and integration into control and prevention program at a local and national level.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.